Your browser doesn't support javascript.
loading
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis.
Chacko, Liza; Karia, Nina; Venneri, Lucia; Bandera, Francesco; Passo, Beatrice Dal; Buonamici, Lodovico; Lazari, Jonathan; Ioannou, Adam; Porcari, Aldostefano; Patel, Rishi; Razvi, Yousuf; Brown, James; Knight, Daniel; Martinez-Naharro, Ana; Whelan, Carol; Quarta, Candida C; Manisty, Charlotte; Moon, James; Rowczenio, Dorota; Gilbertson, Janet A; Lachmann, Helen; Wechelakar, Ashutosh; Petrie, Aviva; Moody, William E; Steeds, Richard P; Potena, Luciano; Riefolo, Mattia; Leone, Ornella; Rapezzi, Claudio; Hawkins, Philip N; Gillmore, Julian D; Fontana, Marianna.
Afiliación
  • Chacko L; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Karia N; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Venneri L; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Bandera F; Heart Failure Unit, Cardiology University Department, IRCCS Policlinico San Donato, Milan, Italy.
  • Passo BD; Department for Biomedical Sciences for Health, University of Milano, Milan, Italy.
  • Buonamici L; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Lazari J; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Ioannou A; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Porcari A; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Patel R; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Razvi Y; Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
  • Brown J; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Knight D; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Martinez-Naharro A; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Whelan C; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Quarta CC; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Manisty C; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Moon J; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Rowczenio D; Barts Heart Centre, The Cardiovascular Magnetic Resonance Imaging Unit, and the Inherited Cardiovascular Diseases Unit, St Bartholomew's Hospital, London, UK.
  • Gilbertson JA; Barts Heart Centre, The Cardiovascular Magnetic Resonance Imaging Unit, and the Inherited Cardiovascular Diseases Unit, St Bartholomew's Hospital, London, UK.
  • Lachmann H; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Wechelakar A; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Petrie A; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Moody WE; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, UK.
  • Steeds RP; Eastman Dental Institute, University College London, London, UK.
  • Potena L; Department of Cardiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
  • Riefolo M; Department of Cardiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
  • Leone O; Division of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Rapezzi C; Division of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Hawkins PN; Division of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Gillmore JD; Cardiologic Center, University of Ferrara, Ferrara, Italy.
  • Fontana M; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Eur J Heart Fail ; 24(9): 1700-1712, 2022 09.
Article en En | MEDLINE | ID: mdl-35779241
ABSTRACT

AIMS:

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed disease. Echocardiography is widely utilized, but studies to confirm the value of echocardiography for tracking changes over time are not available. We sought to describe (i) changes in multiple echocardiographic parameters; (ii) differences in rate of progression of three predominant genotypes; and (iii) the ability of changes in echocardiographic parameters to predict prognosis. METHODS AND

RESULTS:

We prospectively studied 877 ATTR-CM patients attending our centre between 2000 and 2020. Serial echocardiography findings at baseline, 12 months and 24 months were compared with survival. Overall, 565 patients had wild-type ATTR-CM and 312 hereditary ATTR-CM (201 with V122I; 90 with T60A). There was progressive worsening of structural and functional parameters over time, patients with V122I ATTR-CM showing more rapid worsening of left and right ventricular structural and functional parameters compared to both wild-type and T60A ATTR-CM. Among a wide range of echocardiographic analyses, including deformation-based parameters, only worsening in the degree of mitral (MR) and tricuspid regurgitation (TR) at 12- and 24-month assessments was associated with worse prognosis (change at 12 months MR, hazard ratio 1.43 [95% confidence interval 1.14-1.80], p = 0.002; TR, hazard ratio 1.38 [95% confidence interval 1.10-1.75], p = 0.006). Worsening in MR remained independently associated with poor prognosis after adjusting for known predictors.

CONCLUSION:

In ATTR-CM, echocardiographic parameters progressively worsen over time. Patients with V122I ATTR-CM demonstrate the most rapid deterioration. Worsening of MR and TR were the only parameters associated with mortality, MR remaining independent after adjusting for known predictors.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neuropatías Amiloides Familiares / Insuficiencia Cardíaca / Cardiomiopatías Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neuropatías Amiloides Familiares / Insuficiencia Cardíaca / Cardiomiopatías Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
...